Form 4: Edgewise Therapeutics Director Jonathan C. Fox Acquires Shares
SEC Form 4
Director Jonathan C. Fox acquired 559 shares of Edgewise Therapeutics, Inc. on April 1, 2025, through restricted stock units.
Summary
- On April 1, 2025, Jonathan C. Fox, a director of Edgewise Therapeutics, Inc., acquired 559 shares of common stock.
- The acquisition was through the release of restricted stock units.
- The shares were granted as a Quarterly Retainer Award pursuant to the company's Outside Director Compensation Policy.
- Following the transaction, Fox directly owns 11,416 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine transaction. Director acquiring shares is generally a positive signal, but it's part of a compensation plan.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This is a standard disclosure related to insider trading. It is common for directors to receive stock-based compensation.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: Jonathan C. Fox acquired 559 shares of Edgewise Therapeutics through restricted stock units. |
| 04/03/2025 | Date of report: Form 4 filing date. |
Keywords
Edgewise Therapeutics, Director, Share Acquisition, Restricted Stock Units, EWTX, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.